Hammersmith Medicines Research Limited

Hammersmith Medicines Research Ltd, based in London, UK, is a holding company with an active status, having been established 32 years ago in 1993. The company employs 291 people and holds assets worth £17,210,990. It operates from a real address and is overseen by two directors and one owner. Google users rate it 4.0 stars based on 50 reviews. The company regularly imports optical and medical tools and devices (11 months of imports, latest in May 2023), and irregularly exports electrical machinery and equipment (2 months of exports, latest in July 2023).

Hammersmith Medicines Research is a contract clinical research organisation (CRO) specializing in early-phase clinical trials for pharmaceutical and biotechnology companies. Its website details a comprehensive range of services, including trial design, regulatory support, subject recruitment, data management, and specialized procedures like EEG and PET scans. The company boasts extensive facilities, including a 24/7 resuscitation team, 145 beds, and onsite pharmacy and laboratory. It even offers services for food effect studies and thorough QT trials. The company has a good reputation and has completed over 900 trials.

Financially, Hammersmith Medicines Research Ltd shows a mixed picture. Cash bank on hand dropped significantly by 61%, falling to £1.9 million, while accrued liabilities increased by 39% to £950,000. The company's comprehensive income expense plummeted by 330%, resulting in a loss of £1.3 million. However, corporation tax recoverable increased by 15%, and current assets decreased by 4.8% to £17 million. Debtors rose by 17%, suggesting a potential increase in outstanding payments. Despite these challenges, the company’s equity decreased by 3%, and fixed assets remained stable. The company’s bank borrowings increased by 130%, and future minimum lease payments increased by 130%.

The company’s focus on early-phase clinical trials and its extensive facilities suggest a specialized and valuable service. The financial results, however, indicate a period of adjustment, potentially due to increased operating costs or delayed payments. The lack of auditor information, typical for companies of this size, means the financial statements are unaudited. Overall, Hammersmith Medicines Research Ltd appears to be navigating a complex landscape, balancing its specialized services with financial pressures.

Registered in England/Wales under the registration number 02779946, with a registered address at NW10 7EW, London, 44 Cumberland Avenue.

WARNING:The numbers have been rounded for simplicity and may be inaccurate.Please, refer to the latest financial report for verification.